Research
Hormonal
Behavioral sleep deprivation (reduced total sleep hours) causes insulin resistance and glucose intolerance through hormonal dysregulation (increased cortisol, ghrelin, decreased leptin) and increased pro-inflammatory cytokines, thereby increasing the risk of type 2 diabetes mellitus.
Prioritize getting 7-9 hours of sleep nightly. Consistently sleeping less than this is not just about feeling tired; it biologically increases your risk for diabetes by disrupting hormones that control hunger (ghrelin/leptin) and blood sugar regulation (insulin/cortisol).
GoodSupportsHIGH confidence
Sleep deprivation has been associated with multiple physiological changes, including increased cortisol and ghrelin levels, decreased leptin levels and impaired glucose metabolism. Experimental studies have also shown an increase in inflammatory and pro-inflammatory markers... neuro-hormonal changes accompanying this behavioral sleep deprivation may lead to insulin resistance and, subsequently, to diabetes mellitus.
Why this rating
Based on multiple experimental and epidemiological studies cited, though it is a review paper.
Source
Metabolic, Endocrine, and Immune Consequences of Sleep Deprivation
Laila AlDabal et al. · The Open Respiratory Medicine Journal · 2011
DOI 10.2174/1874306401105010031
narrative_reviewCited 354×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Short sleep duration (typically <6-7 hours) is independently associated with an increased risk of obesity in both children and adults, with a dose-response relationship where shorter sleep correlates with higher BMI.Good
- Sleep deprivation and poor sleep quality are associated with an increased risk of developing hypertension and elevated blood pressure.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →